The Manufacturers Life Insurance Company Has $9.24 Million Position in Repligen Co. (NASDAQ:RGEN)

The Manufacturers Life Insurance Company lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 64,199 shares of the biotechnology company's stock after selling 2,468 shares during the period. The Manufacturers Life Insurance Company owned about 0.11% of Repligen worth $9,241,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Ballentine Partners LLC raised its stake in shares of Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock valued at $270,000 after acquiring an additional 72 shares during the period. CIBC Asset Management Inc raised its stake in shares of Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after acquiring an additional 81 shares during the period. GAMMA Investing LLC raised its stake in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 90 shares during the period. Louisiana State Employees Retirement System grew its holdings in Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after purchasing an additional 100 shares in the last quarter. Finally, Peapack Gladstone Financial Corp grew its holdings in Repligen by 5.2% during the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock valued at $301,000 after purchasing an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Price Performance

Shares of RGEN traded down $4.61 during mid-day trading on Friday, hitting $123.24. The company's stock had a trading volume of 580,989 shares, compared to its average volume of 727,651. The firm has a 50-day moving average price of $135.03 and a 200 day moving average price of $145.44. The stock has a market capitalization of $6.92 billion, a price-to-earnings ratio of -241.65, a PEG ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period last year, the company posted $0.28 earnings per share. The business's revenue for the quarter was up 10.4% on a year-over-year basis. On average, research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of recent analyst reports. Canaccord Genuity Group lowered their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Thursday. HC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Royal Bank of Canada dropped their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Finally, Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $173.25.

Insiders Place Their Bets

In related news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.